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AbstrAct
Objectives to analyse the current evidence for the 
management of large vessel vasculitis (lVV) to inform the 
2018 update of the eUlar recommendations.
Methods two systematic literature reviews (Slrs) dealing 
with diagnosis/monitoring and treatment strategies for 
lVV, respectively, were performed. Medline, embase and 
cochrane databases were searched from inception to 31 
December 2017. evidence on imaging was excluded as 
recently published in dedicated eUlar recommendations. 
this paper focuses on the data relevant to giant cell 
arteritis (gca).
Results We identified 287 eligible articles (122 studies 
focused on diagnosis/monitoring, 165 on treatment). the 
implementation of a fast-track approach to diagnosis 
significantly lowers the risk of permanent visual loss 
compared with historical cohorts (level of evidence, loe 
2b). reliable diagnostic or prognostic biomarkers for gca 
are still not available (loe 3b).
the Slr confirms the efficacy of prompt initiation of 
glucocorticoids (gc). there is no high-quality evidence on 
the most appropriate starting dose, route of administration, 
tapering and duration of gc (loe 4). Patients with gca 
are at increased risk of dose-dependent gc-related 
adverse events (loe 3b). the addition of methotrexate or 
tocilizumab reduces relapse rates and gc requirements 
(loe 1b). there is no consistent evidence that initiating 
antiplatelet agents at diagnosis would prevent future 
ischaemic events (loe 2a). there is little evidence to guide 
monitoring of patients with gca.
Conclusions results from two Slrs identified novel 
evidence on the management of gca to guide the 
2018 update of the eUlar recommendations on the 
management of lVV.
InTROduCTIOn
The management of large vessel vasculitis 
(LVV) has rapidly changed in the recent years. 
Imaging is becoming increasingly recognised 
Key messages
What is already known about this subject?
 ► the previous eUlar recommendations for the man-
agement of large vessel vasculitis (lVV) were pub-
lished in 2009. Since then, significant evidence to 
support the diagnosis and treatment of lVV has been 
produced.
What does this study add?
 ► this was the first thorough review of available evi-
dence published until December 2017 guiding diag-
nosis, monitoring and treatment of giant cell arteritis 
(gca).
 ► results of the systematic literature review (Slr) re-
vealed the importance of early diagnosis, including 
the advantages of a fast-track approach to reduce 
ischaemic complications.
 ► rapid initiation of treatment with glucocorticoids 
(gc) is pivotal; the addition of methotrexate or tocili-
zumab reduces relapse rates and gc requirements.
 ► there is inconsistent evidence supporting the use 
of antiplatelet agents to prevent future ischaemic 
events.
 ► there is no high-quality evidence guiding monitoring 
and duration of treatment in gca.
How might this impact on clinical practice?
 ► the results of this Slr will significantly impact the 
future practice on the best diagnostic, monitoring 
and therapeutic approach to gca. the evidence 
summarised in this study formed the basis for a 
substantial revision of the eUlar recommendations 
for the management of lVV, which was recently 
published. the updated eUlar recommendations 
will provide guidance on diagnosis, monitoring and 
treatment of gca in the future years.
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Table 1 Topics addressed by the two SLRs
SLRs informing the 2018 update of EULAR recommendations for the management of LVV
Participants were patients with the following diagnoses: giant cell arteritis or Takayasu arteritis, or other types of LVV (isolated 
aortitis or IgG4-related disease with vasculitis).
SLR 1: Diagnosis, prognosis and monitoring SLR 2: Drug and surgical treatment
 ► Diagnosis: recognition, referral criteria, fast-track 
diagnosis, role of imaging for diagnosis, role of biopsy 
for diagnosis, interdisciplinary workup, considerations 
for subtypes of disease such as cranial/ischaemic/large 
vessel, isolated aortitis, IgG4related disease, LVV disease 
in other vasculitides.
 ► Prognostic and therapeutic implications of disease 
phenotypes: cranial versus extracranial, isolated aortitis, 
other forms including IgG4-related disease, imaging, other 
biomarkers, comorbidities and complications, disease 
damage versus activity.
 ► Long-term follow-up of patients: clinical assessments and 
frequency, imaging, patient-reported outcomes, physical 
therapies and management of complications.
 ► Patient education and other aspects of patients-centred 
care.
 ► Drug therapy: dosing, length of therapy, outcome and 
treatment-related side effects for the following drugs: 
glucocorticoids, methotrexate and other non-biological 
immunosuppressive agents (csDMARDs), tocilizumab and 
other biological DMARDs (bDMARDs).
 ► Specific treatment of organ complications: loss of vision 
and stroke), relapsing, refractory, glucocorticoid-dependent 
disease.
 ► Revascularisation procedures: indications for referral, 
management of aneurysms and/or vessel stenosis.
 ► Adjunctive therapies and prophylaxis: aspirin, cardiovascular 
and cerebrovascular disease, infections, vaccination, 
osteoporosis.
bDMARDs, biological DMARDs; csDMARDs, conventional synthetic antirheumatic drugs ; LVV, large vessel vasculitis; SLRs, systematic 
literature reviews.
as a reliable tool to diagnose LVV.1 2 However, we still lack 
prognostic markers (either derived from baseline char-
acteristics or useful biomarkers) to tailor the intensity of 
treatment to individual patients. Moreover, less common 
types of LVV (eg, isolated aortitis, vascular involvement in 
IgG4-related disease) are emerging, thereby expanding 
the spectrum of disease and adding complexity to their 
diagnosis and management. New therapeutic options are 
available for giant cell arteritis (GCA), offering opportu-
nities, but also challenges in the best treatment approach 
and timing, appropriate concomitant glucocorticoids 
(GC) dose and tapering scheme, as well as potential 
safety concerns.
The aim of this systematic literature review (SLR) was to 
collect evidence on the therapeutic management of LVV 
to inform the Task Force responsible for the 2018 update 
of the EULAR LVV recommendations.3 This, together 
with a second SLR focused on diagnostic and monitoring 
aspects in LVV, provided the Task Force with the current 
state of evidence. This paper will provide the evidence 
that emerged from both SLRs, focusing on the evidence 
in GCA. A second publication will deal with results of the 
two SLRs regarding Takayasu arteritis (TAK) and other 
types of LVV.
MeTHOds
Two SLRs were performed according to the EULAR oper-
ating procedures.4 MEDLINE, EMBASE and Cochrane 
CENTRAL library were searched from inception of each 
database (1946, 1974 and 1993, respectively) to 31 of 
December 2017. Detailed description of search strategies 
is provided in the online supplementary material (online 
supplementary file 1). There was no language restric-
tion. References from included studies were screened. 
Two SLRs were performed by two different reviewers 
according to research topic (table 1). We included all 
study designs (except case reports of single patients). 
Meta-analyses and SLRs were reviewed and included if 
relevant. Diagnostic and monitoring aspects regarding 
the use of imaging in LVV were excluded due to the 
recent publication of dedicated EULAR recommenda-
tions and a SLR on the use of imaging for LVV.1 2
Two reviewers (SM and AFA) independently screened all 
titles and abstracts to identify eligible studies to be assessed 
by full text. Both reviewers independently extracted data 
from eligible papers and summarised the evidence into 
summary of evidence (SoE) tables using a standardised 
data extraction form. Complete SoE tables are published 
in the online supplementary material. Included studies 
were organised according to diagnosis (GCA vs TAK vs 
other forms of LVV) and according to research question 
(type of diagnostic tool, biomarkers, monitoring tools, 
outcome assessment or type of drug or surgical interven-
tion). Following the 2014 operating procedures and the 
2017 additional guidance document on the development 
of EULAR recommendations, levels of evidence (LoE) 
were assigned according to the 2009 Oxford Centre for 
Evidence-Based Medicine LoE.5 Risk of bias (RoB) was 
assessed using the Cochrane Risk of Bias Assessment Tool6 
for randomised controlled trials (RCTs) and the Newcas-
tle-Ottawa scale for observational studies.7 The Quality 
Assessment of Diagnostic Accuracy Studies II and the 
Quality In Prognosis Studies were used for observational 
studies according to specific outcomes studies.4 6 8
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Table 2 Retrospective cohort studies comparing a fast-track diagnostic strategy for GCA to conventional practice
Study ID N Variable assessed FTA
Conventional 
practice P value NOS scale
Patil et al, 201519 113 Permanent visual 
impairment (n; (%))
6 (9%) 17 (37%) 0.001 2
  Time from symptoms to 
diagnosis
(median (range) days)
17.5 (0–206) 21.0 (1–196) >0.2
Diamantopoulos et al, 
201620
75 Permanent visual 
impairment(n)
1 (1.3%) 6 (8%) 0.01* 2
*Relative risk: 0.12 (95% CI 0.01 to 0.97).
.FTA, fast-track approach; GCA, giant cell arteritis; NOS, Newcastle-Ottawa Scale.
ResulTs
The SLR focused on diagnosis and monitoring of all 
types of LVVs yielded 4389 articles and the one focused 
on treatment yielded 6226 articles (after removal of 
duplicates). One hundred and twenty-two and 165 
studies, respectively, were finally included for full-text 
review. Of these, 62 and 76 studies, respectively, focused 
on GCA. Details are described in the online supplemen-
tary file 1. A meta-analysis of the collected evidence was 
not performed due to pronounced heterogeneity of the 
included studies in terms of design, inclusion criteria, 
methodology, type of intervention and outcome.
General management and diagnosis
Disease patterns of gca
Standardised definitions for different disease patterns 
are lacking, leading to difficulties in comparability 
between studies. Nevertheless, 12 papers focusing on 
disease subtypes in GCA and on their clinical and prog-
nostic implications were retrieved. Patients with large 
vessel GCA (LV-GCA) are more likely to be younger9–11 
and female12 13 and suffer from a longer diagnostic 
delay11 12 14 compared with those with exclusively cranial 
involvement. Headache, jaw claudication, scalp tender-
ness and visual complications are less frequent,11–13 15 
as opposed to a higher frequency of limb claudication 
and symptoms of polymyalgia rheumatica (PMR).11 13 14 
Relapse rates have been reported to be higher in LV-GCA 
(4.9 vs 3.0/10 person-years; p<0.001)14 15 with discordant 
results on the need for more intensive immunosuppres-
sive regimens.11 12 14–17 LV involvement with aortic aneu-
rysm/dissection is associated with increased mortality in 
GCA.18
In summary, disease patterns of GCA are mainly repre-
sented by cranial and LV-GCA. This distinction may have 
clinical and prognostic implications (LoE 3b).
Fast-track clinics for the diagnosis of gca
There were two retrospective cohort studies (total 
number of patients n=189) comparing conventional 
clinical practice to a fast-track approach (FTA) inte-
grating clinical evaluation with ultrasonographic 
assessment of the temporal (TA) and axillary arteries 
(table 2).19 20 Compared with historical cohorts, the FTA 
has been associated with a significant reduction in the 
rates of visual loss,19 20 inpatients costs20 and need for 
temporal artery biopsy (TAB)21 (LoE 2b).
role of taB in gca
The SLR retrieved 13 retrospective observational cohort 
papers22–34 and only three prospective studies,35–37 
focusing on the diagnostic role of TAB and on the asso-
ciated clinical features. The data showed the importance 
of performing TAB as soon as possible, since in one large 
study including 381 patients sensitivity decreased rapidly 
with high dose of GC treatment (48% within 3 days vs 33% 
≥7 days).35 Nevertheless, another study on a large cohort 
of 535 consecutive patients had shown similar rates of 
TAB positivity regardless of previous GC treatment (31% 
in untreated patients vs 35% in patients exposed to GC 
before TAB; p=0.4). The frequency of positive TABs 
reduced with ongoing GC therapy >7 days but persisted 
in 28% of cases treated with GC for over 2 weeks. Inter-
estingly, TABs were re-evaluated by a pathologist blinded 
to clinical and treatment information. Moreover, one 
small longitudinal pathological study (40 patients with 
initial positive TABs) has shown that vasculitis may still 
be demonstrated on repeated biopsies obtained after 
3 (n=10), 6 (n=12), 9 (n=9) or 12 months (n=9) of GC 
therapy but with decreasing probability: 70% at 3 months, 
75% at 6 months, 44% at 9 and 12 months, respectively.36
The recently published study on the Role of Ultra-
sound compared with Biopsy of Temporal Arteries in the 
Diagnosis and Treatment of GCA (TABUL) has reported 
a TAB sensitivity against clinical diagnosis of 39%, with 
100% specificity.35 Assessing the diagnostic performance 
of TAB has some limitations in GCA since an absolute 
reference standard for diagnosis is still lacking. The refer-
ence clinical diagnosis used in TABUL incorporated TAB 
results as part of ACR criteria, but also clinician’s final 
diagnosis, emergence of complications consistent with 
GCA during follow-up or the emergence of alternative 
diagnosis and the validation by an expert review panel.
The length of TAB is crucial for optimising diagnostic 
performance. The cut-off with the highest positive predic-
tive value for a positive TAB has been reported to be 
≥0.7 cm after specimen fixation.22 35 A single retrospective 
multicentre study has suggested that in the presence of 
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inflammatory infiltrate involving the media and media–
intima junction (excluding lymphocyte infiltration 
isolated to the adventitial or periadventitial tissue) the 
cut-off to optimise sensitivity for an histological confir-
mation of GCA should be ≥0.5 cm.38
Histological patterns of inflammatory infiltrate distri-
bution (eg, transmural) on TAB have been correlated 
with specific clinical manifestations (eg, typical cranial 
symptoms for GCA).23 Discordant evidence was found 
in regard to the presence of giant cells on TAB with the 
risk of blindness or cranial ischaemic events.24–26 The 
presence of giant cells and calcifications on TAB have 
been described as independent predictors for the devel-
opment of permanent visual loss.32 Giant cells have also 
been linked with a relapsing disease course,27–29 but not 
with GC requirements.24 30 37
In summary, TAB is a highly specific test to confirm 
a diagnosis of GCA (LoE 1b), however, diagnostic yield 
depends on timing after treatment initiation and correct 
sampling. There are no consistent data supporting a 
prognostic role for TAB on disease course or outcome.
implications of disease activity, damage, comorbidities and 
complications on gca
Several observational studies have explored potential 
predictors of ischaemic complications in GCA. Transient 
visual ischaemic symptoms,39 40 cerebrovascular acci-
dents,41 jaw claudication,39 42 headache, TA tenderness39 
and an increased platelet count39 have been reported as 
risk factors for visual complications. On the other hand, 
PMR, upper limb artery involvement, constitutional 
symptoms, elevated C reactive protein (CRP) and low 
haemoglobin (Hb) levels conferred a reduced risk.39 43 44 
Cerebrovascular accidents in GCA have been associated 
with the presence of comorbidities, namely hyperten-
sion45–47 and hyperlipidaemia,45 but negatively correlated 
with anaemia and female sex.45 46
Relapses are more frequent in the first year after diag-
nosis48 and are more common among patients presenting 
with scalp tenderness, PMR and evidence of a strong 
inflammatory response (at least three of the following: 
fever >38°C, weight loss ≥4 kg, Hb <11 g/L and erythro-
cyte sedimentation rate (ESR) ≥85 mm/hour).49–51 A 
relapsing course is associated with higher GC require-
ments and higher rates of methotrexate (MTX) use.49
The rate of occurrence of vascular complications in 
GCA is high within the first year from diagnosis (5 events 
per 100 person-years). The risk of development of aortic 
aneurysms/dissection increases over time, particularly 
after 5 years from diagnosis, and has been reported to 
occur up to 20%–30% of patients. The aortic diameter 
(assessed by CT) increases over time and is more signif-
icant in the ascending and descending aorta, occurring 
mostly at the expense of patients with aortic structural 
damage at the first CT. In a cohort of 54 patients with 
GCA, followed prospectively for a median of 10.3 years 
after initial screening, reassessments with contrast-en-
hanced thoracic CT and ultrasound of the abdominal 
aorta performed at least every 4 years, or according to 
clinical judgement in the presence of abnormal findings 
at first assessment, allowed to detect aortic structural 
damage in 33.3% of patients. Aortic damage was defined 
as a focal dilatation, or a diffuse dilatation with a diam-
eter ≥4 cm in the thoracic aorta and ≥3 cm in the abdom-
inal aorta). Surgical repair, although indicated in at least 
50% of cases, was only feasible in about one-third, mainly 
due to advanced age and comorbidities.52 Interestingly, 
the size of the aneurysm has not been associated with the 
risk of dissection/rupture in patients with GCA, and a 
role of ongoing active inflammation of the vessel wall has 
been suggested.18
Aortic involvement is associated with a fivefold increase 
risk of death, while the mortality of GCA in general is 
not increased.18 52 Mortality has also been associated with 
male sex and visual loss.53 54 Severe infections and GC 
dose above 10 mg/day of prednisone after 12 months of 
treatment represent a significant mortality risk (HR 3.19, 
95% CI 1.76 to 5.53; p=0.025 and HR 1.93, 95% CI 1.08 to 
3.47; p=0.0001, respectively). An increased risk of infec-
tion-related mortality was confirmed in diabetic patients, 
further enhancing the need for careful management of 
comorbid conditions in patients with GCA.55
Overall, evidence points to a possible prognostic and 
predictive role of specific presenting symptoms with 
ischaemic complications and poor outcome (LoE 3b). 
Comorbidities can influence GCA-related complications 
and their management should be integrated in the treat-
ment of GCA (LoE 2b).
Biomarkers for gca
The SLRs found 24 observational studies that analysed 
(mostly circulating) biomarkers and their relation to 
disease outcome (online supplementary file 2, tables 
19–24). The most widely used biomarkers for GCA have 
been ESR and CRP. A stronger inflammatory response 
(including systemic symptoms and/or markedly 
increased ESR or CRP) is associated with a decreased risk 
of ischaemic events,56 57 but higher risk of relapse.51 58
Although infrequent, there are reports of patients 
with GCA with active disease that present with normal 
or near-normal ESR and/or CRP. In a prospective series 
of 25 untreated patients,59 four presented ESR levels 
below 20 mm/hour with no clinical differences from the 
patients with high ESR. On this study, IL-6 levels were 
measured, and despite appearing more sensible than 
ESR to detect disease activity, of the four patients with 
normal ESR, two also had normal IL-6 levels. CRP closely 
followed IL-6 trend. As tocilizumab (TCZ) suppresses the 
CRP and other acute phase reactants production in the 
liver, CRP, and indirectly, ESR levels (eg, secondary to 
fibrinogen and acute phase reactants reduction) may not 
accurately reflect disease activity in TCZ treated patients 
with GCA and the search for alternative biomarkers is 
desirable.
Circulating levels of several cytokines (eg, IL-6 and 
TNF-alpha) have been associated with a relapsing course 
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of GCA, with levels falling once remission had been 
obtained.60–62 High IL-6 levels have been inversely asso-
ciated with ischaemic events.63 Osteopontin has recently 
been proposed as a marker of active disease especially in 
patients treated with TCZ.64 Although osteopontin levels 
correlate with IL-6 levels, its production in cultured 
arteries was shown not to be significantly modified by 
TCZ.64 Therefore, osteopontin is an interesting candi-
date biomarker for TCZ-treated patients with GCA, but 
prospective clinical data correlating osteopontin levels 
with imaging and clinical outcomes are yet lacking.
The association between antiphospholipid antibodies 
and ischaemic complications in GCA is controversial.65–68 
Genetic biomarkers for GCA are still under investigation 
(online supplementary file 2; table 19).
In summary, validated, reliable biomarkers for GCA are 
still not available. ESR and CRP are the most widely used 
and correlate to some extent with disease activity (LoE 
3b), but the reliability of CRP in TCZ-treated patients 
with GCA still needs to be addressed.
long-term follow-up of patients including clinical assessment, 
physical therapy
The SLRs could not find evidence regarding the best 
timings/frequency of follow-up visits nor was there any 
data on the role of physical therapy.
Patient-reported outcome measures and patient-centred care in 
gca
One prospective study looked at the efficacy of a patient 
education programme for patients with different types of 
vasculitis (including nine patients affected by GCA). A 
significant increase in the awareness on the disease was 
confirmed 1 and 12 months after the training.69
drug therapy
glucocorticoids
The SLRs yielded four RCTs assessing the use of GC, 
all including newly diagnosed patients with GCA.70–73 
Details are presented in table 3. Two RCTs investigated 
the GC-sparing effect of high-dose pulse intravenous 
methylprednisolone induction therapy; one of these had 
a high RoB as the study was not blinded.73 Notably, both 
RCTs on the use of high-dose intravenous GC excluded 
patients with recent vision loss or ocular/vascular compli-
cations. The GC regimens used differed between the two 
studies: 15 mg/kg intravenous methylprednisolone for 3 
days followed by 40 mg/day oral prednisone with rapid 
tapering,71 or 240 mg intravenous single pulse of methyl-
prednisolone, followed by 0.5–0.7 mg/kg/day oral pred-
nisone with rapid tapering, respectively.73 Only the first 
study met the primary endpoint allowing a more rapid 
GC tapering in patients treated with 3 days of intrave-
nous pulses at diagnosis, with 71% of patients reaching 
a prednisone dose ≤5 mg/day by week 36 compared with 
15% for patients not receiving pulse intravenous meth-
ylprednisolone; p=0.003 and a reduction by 2224 mg in 
the cumulative prednisone dose (dose of GC pulses not 
counted).71
One small RCT, including seven patients in the active 
group and five in the control group, analysed the effi-
cacy and safety of modified-release prednisone with 
immediate-release prednisolone in newly diagnosed 
GCA suggesting a similar outcome profile, but with worse 
sleeping scores in the modified-release GC. However, the 
small sample size does not permit definitive conclusions.70 
The differential effect on bone mass loss of deflazacort 
versus prednisone was assessed in an RCT showing no 
difference between the two GC compounds.72
Data on the most effective initial GC dose to treat GCA 
derive from uncontrolled observational studies with no 
conclusive evidence to be drawn and no apparent influ-
ence on the maintenance dose.74–76 In a retrospective 
review of 286 TAB +patients with GCA, a higher initial 
oral prednisone dose (>40 mg/day) was associated with 
greater chances of reaching a low dose sooner (HR 1.46; 
95% CI 1.09 to 1.96) and of discontinuing GC (HR 1.56; 
95% CI 1.09 to 2.23).48
The incidence of visual loss (defined as new onset 
of permanent reduction of visual acuity or visual field 
loss) with respect to early diagnosis and GC initiation 
compared with delayed treatment was assessed in a 
prospective longitudinal cohort study of 68 patients with 
GCA, suggesting the importance of prompt treatment in 
reducing the rate of permanent visual loss. This approach 
did not have any effect on the frequency of relapses.77 
Further evidence from a retrospective, multicentre study 
supports the concept that partial improvement of visual 
acuity is associated with the very early initiation of GC 
within 1 day from the onset of visual symptoms, regard-
less of the route of administration.78
The effect of the best route of administration of GC 
(intravenous vs oral) on visual loss in GCA was assessed 
in a retrospective longitudinal cohort study. Patients 
either received 150 mg dexamethasone sodium phos-
phate every 8 hours for 1–3 days, followed by oral predni-
sone 80–120 mg/day, or they were given oral prednisone, 
starting with doses ≥80 mg/day. Visual improvement only 
occurred in a very limited number of cases (only in 4% of 
eyes and only for overall visual acuity and not for central 
vision) with no differences in the route of GC administra-
tion. Earlier GC initiation was associated with a trend for 
greater likelihood of improvement.79 Another retrospec-
tive longitudinal study compared the route of GC admin-
istration during the first week of treatment on visual loss 
at presentation of GCA. Different intravenous schemes 
were used (intravenous methylprednisolone pulses 
1000 mg per day, 250 mg 2–4 times per day, 500 mg 1–2 
times per day for a median of 3 days (range 2–5 days)) 
compared with oral GC prednisolone (50–100 mg/day). 
There was an increased likelihood for improved visual 
acuity in the group treated with intravenous GC (40%) 
compared with the oral route (13%); in all except for 
four patients, vision remained stable 1 month after 
presentation, supporting the idea that improvement 
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only occurs in the very initial phases of the ischaemic 
process.80 Notably, both studies were characterised by 
high RoB; different baseline characteristics of the two 
cohorts and different GC doses limited the comparability 
and possibility to achieve firm conclusions.
The most effective GC tapering scheme was not specif-
ically assessed in any study included in the SLRs. In the 
trial of TCZ in GCA (GiACTA),81 two standardised pred-
nisone-taper protocols (52 week and 26 week taper) were 
tested in an RCT. Patients who enrolled in the placebo 
group with more rapid tapering protocol experienced 
more flares (68% vs 49%) and a greater need for pred-
nisone escape therapy (74% vs 55%), with a comparable 
safety profile. Nevertheless, the cumulative GC dose was 
numerically lower for the group treated with a more 
rapid GC taper (3296 vs 3818 mg).
The safety of GC treatment was evaluated in a large 
nested case–control analysis demonstrating a strict 
correlation between prednisone dose (average daily GC 
dose >30 mg/day) and the development of diabetes with 
an adjusted OR of 4.7 (95% CI 2.8 to 78), glaucoma 
3.5 (2.0–6.1), osteoporosis 1.9 (1.2–2.9), fractures 2.6 
(1.6–4.3), serious infections 3.3 (2.2–5.2) and death 2.1 
(1.3–3.5).82 Similar concerns regarding the significant 
rate of GC-related adverse events (AEs) were confirmed 
in a retrospective medical claims data analysis, reporting 
an increase in HR by 3% for every 1000 mg increase in 
prednisone-equivalent exposure.83
Evidence for GC discontinuation and drug-free remis-
sion was evaluated in a retrospective cohort study demon-
strating that the following factors were associated with 
higher chances of obtaining long-term remission: a lower 
number of flares, lower cumulative GC dose at 1 year, 
lower duration of GC treatment and more rapid achieve-
ment of low-dose GC.84
In summary, the prompt initiation of GC therapy is 
consistently associated with a better outcome, including 
visual complications (LoE 4). Only low to moderate 
quality evidence with conflicting results exists on the 
most appropriate initial dose and route of administra-
tion (LoE 4). The most appropriate tapering scheme has 
not been standardised yet, with evidence from one high-
quality RCT suggesting a higher risk of flares in more 
rapid tapering regimens (LoE 1b). Nevertheless, safety 
concerns related to GC are dose dependent (LoE 3b), 
underlying the need to optimise the dose and duration 
of GC treatment.
MTX and other non-biological immunosuppressive drugs
The role of MTX in addition to GC for the treatment 
of GCA has been tested in four RCTs.85–88 All studies 
included newly diagnosed patients. The fourth RCT 
enrolled only a limited number of untreated GCA (n=6) 
and/or patients with PMR and presented a significant 
RoB.88 Only one of the RCTs had an overall low RoB.87 
Just one trial met the primary endpoint (reduction in 
number of relapses and total cumulative dose of GC 
during follow-up).86 No effect on the relapse rate, total 
dose and duration of GC was reported by the RCT from 
Hoffman et al.85 In all studies, the dose of MTX was gener-
ally low, administered orally and differed significantly 
among the RCTs: maximum dose ranged from 15 mg/
week, down to 7.5 mg/week (for two RCTs), respectively. 
Moreover, the concomitant GC dose was not standard-
ised among the studies, nor was the GC duration and 
tapering scheme.
An individual patient data meta-analysis pooling infor-
mation from 161 patients enrolled in the three RCTs 
performed exclusively on patients with GCA85–87 re-eval-
uated the efficacy and safety of adjunctive low-dose MTX 
in GCA.89 HRs compared with placebo for a first disease 
relapse are 0.65 (95% CI 0.44 to 0.98; p=0.004), for a 
second relapse: 0.49 (95% CI 0.44 to 0.98; p=0.02). A 
superiority of the treatment effect of MTX over placebo 
becomes apparent after 24–36 weeks, suggesting that the 
duration of follow-up might have influenced the possi-
bility to reach the endpoint in the individual trials. At 
least 3.6 (95% CI 2.2 to 56.8) and 4.7 (95% CI 3.3 to 
21.9) patients need to be treated with MTX to prevent a 
first and second relapse, respectively. The adjunctive use 
of MTX resulted in a significant reduction in the cumula-
tive GC dose by 842 mg within 48 weeks. Finally, MTX was 
associated with higher probability of reaching a sustained 
drug-free remission (HR 2.84; p<0.001). The overall 
incidence of AEs was not significantly different between 
patients treated with MTX versus placebo.
The effectiveness and safety of MTX in real life has been 
reported by one observational retrospective longitudinal 
study describing the role of long-term (up to 8.4 years) 
continuation of MTX in routine clinical practice for 
patients with GCA (both as first line in newly diagnosed 
patients or as add-on treatment in relapsing cases).90 In 
this study, the maximum MTX dose was 15 mg/week, and 
the drug proved to be safe and with low discontinuation 
rates due to inefficacy (incidence rate for discontinua-
tion: 2.8/100 patient-years). However, the RoB is high 
due to the study design and lack of a comparator group.
Cyclosporine was not efficacious and did not display 
a GC-sparing effect in two open RCT including newly 
diagnosed and refractory cases of GCA.91 92 Azathio-
prine (AZA) efficacy was tested in an RCT with signifi-
cant methodological issues influencing the results of 
the study.93 Dapsone was tested in an open, prospective 
randomised trial versus GC alone but did not demon-
strate a GC-sparing effect. Haematologic toxicity with 
dapsone is relevant and warrants periodic monitoring.94 
A summary of the RCTs of non-biological immunosup-
pressants in GCA is presented in table 4.
Leflunomide and cyclophosphamide effectiveness and 
safety were only assessed in retrospective cohort studies 
not allowing for definitive conclusions.95–99
In summary, MTX can reduce the risk of relapse and 
exposure to GC in patients with GCA (LoE 1a). No high-
quality evidence supports the efficacy of other conven-
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TCZ and other biological immunosuppressive drugs
The SLRs revealed two multicentre double-blind, place-
bo-controlled RCTs on the use of TCZ for patients 
with GCA (newly diagnosed/relapsing/LV-GCA)81 100 
(table 5). One RCT (n=251 patients) tested two schemes 
of TCZ s.c. (162 mg every week or every other week) with 
two GC tapering protocols (26 weeks or 52 weeks). The 
other study (n=30 patients) assessed the use of intrave-
nous TCZ (8 mg/kg/monthly). The primary outcome 
was met in both studies. In the larger Trial of Tocilizumab 
in Giant Cell Arteritis (GiACTA) trial, sustained GC-free 
remission at week 52 was 56% (TCZ/weekly) and 53% 
(TCZ/every other week) vs 14% (26 week GC taper) or 
18% (52 week GC taper); p<0.001. The HR for flares was 
0.23 (99% CI 0.11 to 0.46) vs 0.28 (0.12 to 0.66); p<0.001 
compared with patients receiving a 26-week taper (of GC 
alone). Sensitivity analyses excluding CRP normalisation 
from the definition of remission confirmed the results. 
The weekly TCZ dose was more efficacious in preventing 
flares in relapsing disease compared with the every-other-
week regimen. The cumulative median GC dose over 52 
weeks was significantly lower for the group receiving TCZ 
(1862 mg) compared with both GC schemes (3818 mg 
for the 52-week taper and 3296 for the 26-week taper); 
p<0.001 for both comparisons.81
In the trial from Villiger et al, complete remission was 
achieved by week 12 in 12/20 (85%) patients treated with 
TCZ (at a GC dose 0.1 mg/kg/day) vs 4/10 (40%) in the 
comparator group; risk difference was 45% (95% CI 11% 
to 79%; p=0.03). The cumulative prednisolone dose after 
52 weeks was 43 mg/kg in the TCZ group vs 110 mg/kg 
in the placebo group (p=0.005).100 No safety issues arose 
from the two RCTs. The RoB was low for both studies 
(online supplementary file 3; table 37).
Three retrospective open-label cohort studies101–103 and 
two case series104 105 were identified assessing the role of 
intravenous TCZ in patients with refractory GCA, GC-de-
pendent disease or those with AE to GC. Effectiveness was 
confirmed in these observational studies, with few serious 
AE reported (five serious infections with two deaths, one 
tuberculosis infection). One of these case series reported 
on the long-term (median follow-up of 2 years) good 
tolerability of intravenous TCZ in eight patients with 
GCA. The RoB was high for all these studies.
The optimal duration of TCZ therapy to ensure 
sustained remission has not been assessed yet, with data 
on case series suggesting frequent relapses after TCZ 
discontinuation (up to 35% after 3.5±1.3 months).101 106
The efficacy of intravenous abatacept (ABA) (10 mg/
kg on days 1,15, 29 and then every 8 weeks) was assessed 
in a multicentre, double-blind placebo-controlled RCT 
enrolling 41 newly diagnosed or relapsing patients 
with GCA or LV-GCA. After 12 weeks of treatment with 
ABA, patients were randomised to either continue with 
the active drug or with placebo (GC). The trial demon-
strated a marginally significant reduction in the risk of 
relapse compared with GC alone (relapse-free survival 
rate at 12 months: 48% vs 31%; p=0.049) and a longer 
median duration of remission (9.9 months vs 3.9 months; 
p=0.023), without increased toxicity. GC-sparing effect 
of ABA was not assessed.107 The RoB was generally low 
(online supplementary file 3; table 37), however, the 
results obtained by the study were at the limits of statis-
tical significance.
The SLRs identified three multicentre, double-blind 
placebo-controlled RCTs of TNF inhibitors (TNFi)–adali-
mumab (ADA), etanercept (ETA) and infliximab (IFX) 
for GCA.108–110 Efficacy in terms of GC-sparing effect, 
disease activity and GC withdrawal or reduction of GC 
cumulative doses and AE was not confirmed by any of 
the studies using TNFi, with two of them (ETA, IFX) 
being limited by the low number of patients included. All 
studies, but the one on IFX,110 had a high RoB.
An open-label proof-of-concept study testing the 
steroid-sparing effect of ustekinumab in 14 patients with 
refractory GCA was identified, showing promising results 
in terms of GC dose reduction from baseline to last 
follow-up (from 20 to 5 mg/day; p=0.001).111
In summary, TCZ significantly enhances the chances of 
achieving remission, preventing flares and reducing GC 
requirements in newly diagnosed and relapsing patients 
with GCA (LoE 1b). The duration of treatment (beyond 
1 year) and long-term safety have not yet been prospec-
tively assessed.
Specific treatment of organ complications (including visual loss 
and stroke)
Evidence for specific treatment of visual loss was only 
found for GC treatment and has been described in the 
section above. There was no evidence regarding the 
management of other ocular complications resulting 
from treatment (eg, cataract and glaucoma). There was 
no evidence for specific treatment to prevent cerebrovas-
cular accidents associated with GCA.
relapsing and refractory gca
We identified descriptive longitudinal cohorts assessing 
the treatment and outcome of patients with relapsing 
GCA. Most relapses occurred during GC monotherapy 
with increasing risk at lower doses ≤10 mg/day.112 A 
relapsing course was associated with higher and more 
prolonged GC requirements and related GC side effects, 
particularly osteoporosis.27 49 MTX 15 mg/week was often 
added for relapses, particularly in cases with ≥2 relapses 
or the presence of GC side effects together with an 
increase in GC dose by 10–15 mg/day above the previous 
effective dose.
The individual patient data meta-analysis from Mahr 
et al provided evidence supporting the role of MTX in 
the prevention of a second relapse.89 The GiACTA trial 
(described above) included a specific analysis of patients 
with refractory/relapsing disease, showing that the only 
effective dose of TCZ in this group was 162 mg/weekly 
and not every other week.81
Overall, TCZ (LoE 1b) and MTX (LoE 1a) have shown 
evidence for reduction of further relapses in GCA.
Lisbon. P
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Revascularisation procedures (aneurysm and stenosis 
treatment)
Two studies retrospectively assessed the treatment of 
aortic aneurysms (and/or dissection) in GCA.113 114 The 
surgical outcome and short-term survival were good, but 
with the need for frequent surveillance and occasional 
requirement for repeated intervention (8%–10% of 
cases).
There were no studies addressing the role of preven-
tive medical treatment or timing for screening for aortic 
complications.
One retrospective case series (n=10 LV-GCA patients) 
described the outcome of percutaneous transluminal 
balloon angioplasty (PTA) in combination with GC, 
csDMARDs and antiplatelet agents for symptomatic 
upper limb stenosis/occlusion resistant to medical treat-
ment. The rate of restenosis was high (primary patency 
rate 65.2%), but repeated PTA was effective (secondary 
patency rate 82.6%).115
A retrospective case series including 10 patients with 
LV-GCA or TAK analysed the safety and effectiveness of 
PTA for occlusive arterial disease in LVV, which were 
in accord with previous evidence. Technical success 
was good for stenotic lesions and moderate for occlu-
sive lesions; the cumulative primary clinical success rate 
was 67.6%. There is an important risk of arterial injury 
during PTA, reported in 36% of patients.116
Overall, we found only limited and low-quality data to 
guide revascularisation procedures in patients with GCA 
(LoE 4).
Adjunctive therapy and prophylaxis (aspirin, other 
cardiovascular complications, infections, osteoporosis)
The SLRs identified six retrospective longitudinal cohorts 
studies investigating the role of antiplatelet agents 
to prevent ischaemic complications in GCA.47 117–121 
The results of the studies are controversial, with three 
suggesting no effect of acetylsalicylic acid (ASA) in 
preventing ischaemic events when prescribed before or 
at the time of GCA diagnosis117 118; and one suggesting an 
association with increased risk for severe cranial ischaemic 
events.47 By contrast, two studies reported that anti-
platelet/anticoagulation therapy might reduce ischaemic 
complications at diagnosis and during follow-up without 
any increased risk of bleeding.119 122 There have been no 
RCTs assessing the use of low-dose ASA for GCA.123 A 
meta-analysis of six retrospective studies (including 914 
patients) concluded that established antiplatelet/antico-
agulants given prior to diagnosis do not reduce the risk 
of ischaemic events. The heterogeneity of the studies was 
moderate/high.
The role of statins in GCA is unclear. Contradictory 
results were obtained from two population-based inci-
dent cases cohorts124 125 and two retrospective longitu-
dinal cohorts.126 127 The first two studies (characterised 
by a lower RoB) reported that statin therapy, given prior 
to126 127 or within 1 year from the diagnosis of GCA,127 
was associated with reduced hospitalisation due to 
cardiovascular events in GCA (HR 0.993; 95% CI 0.986 
to 0.999; p=0.0467). There was no effect of statins on the 
inflammatory process or on the rapidity of GC reduction. 
The retrospective observational studies did not demon-
strate any reduction in the incidence of severe ischaemia 
and/or any steroid-sparing effect.
Concomitant treatment with angiotensin receptor 
blockers (ARB) but not with ACE inhibitors (ACEI) was 
associated with lower relapse rate and more prolonged 
disease-free survival in GCA in a single prospective, open-
label controlled study (adjusted HR for relapses with 
ARB 0.32; 95% CI 0.12 to 0.81; p=0.017).128 Of the 106 
patients included, only 36 received ACEI and 14 were 
treated with ARB. Although patients had been followed 
up prospectively, data were analysed retrospectively. 
Finally, duration, dose and type of ARB treatment were 
heterogeneous. Therefore, these results need confirma-
tion by further studies.
The SLRs identified two studies assessing the role of 
prophylaxis against Pneumocystis jiroveci pneumonia (PJP). 
In one prospective cohort of 62 patients treated with GC 
(20–50 mg/day) combined with MTX (15–20 mg/week), 
there were 4 (6%) cases of PJP. The main risk factor 
identified for PJP infection was the presence of lymph-
opaenia. The other study was a retrospective case series 
(seven patients) reporting 29% mortality in patients with 
GCA who developed PJP infections.129 130 Although both 
studies raised the issue of infection screening and the risk 
of infection in these elderly patients treated with inten-
sive immunosuppressive regimens, they did not provide 
any clear evidence on the modality or timing of antibiotic 
prophylaxis to prevent infectious complications.
The prevention and treatment of osteoporosis, the 
management of medium to high-dose GC therapy and 
vaccinations have not been assessed specifically for 
GCA. International consensus recommendations on the 
management of osteoporosis and vaccinations in rheu-
matic diseases in general have been published.131 132
In summary, there is no consistent evidence that anti-
platelet agents given at the time of GCA diagnosis prevent 
future ischaemic events (LoE 2a). Otherwise there is no 
strong evidence on other adjunctive or prophylactic ther-
apies specifically for GCA.
dIsCussIOn
The management of GCA has recently been improved 
as a result of more standardised and widespread intro-
duction of diagnostic imaging tools, newer therapies 
(particularly bDMARDs) and optimised therapeutic and 
monitoring strategies. Two SLRs were required to inform 
an update of the recommendations on the management 
of LVV supported by the EULAR Task Force. The SLRs 
provided more evidence than the previous recommenda-
tions133 because they were conducted from inception of 
all available literature to ensure a more systematic assess-
ment of the evidence in LVV. The Task Force agreed 
to include all study designs (except for case reports of 
Lisbon. P
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single patients) in the SLRs, in order to offer a compre-
hensive overview of all available evidence to support clin-
ical decisions in a field of rare diseases with very limited 
numbers of RCTs/high LoE studies. The inclusion of 
observational studies reflecting routine care improves 
the generalisability of our results but introduces a higher 
RoB and confounding elements that need to be taken 
into account when interpreting these findings. Informa-
tion from the online supplementary material should be 
considered together with the present paper. Moreover, 
it needs to be considered that research on LVV is an 
evolving field, but the SLR included evidence published 
until the 31 December 2017 in order to provide evidence 
for the 2018 update of the EULAR recommendations on 
the management of LVV.
The increasingly recognised role of imaging, espe-
cially ultrasound and fast-track clinics, in the diagnosis of 
GCA has been incorporated into the recently published 
EULAR recommendations on imaging of LVV1 and 
should allow earlier diagnosis and better characterisa-
tion of the frequency and types of disease patterns in the 
future.
The SLR on the general management and monitoring 
mainly retrieved studies with a low LoE, underlying the 
need for future high-quality research aiming at clarifying 
the precise prognostic role of disease phenotypes (cranial 
vs LV-GCA),134 the assessment of reliable predictors and 
preventive strategies for future complications (including 
ischaemic events and development of aneurysms), the 
optimal follow-up timing and tools to detect disease 
relapses. Moreover, the identification of biomarkers of 
disease severity and activity which could prove useful 
during treatment with TCZ (in view of its direct effect in 
suppressing CRP) is gaining increasing interest.
The SLR focusing on treatment confirmed the need to 
promptly initiate GC therapy as soon as the diagnosis of 
GCA is suspected, however, there are conflicting data on 
the optimal starting dose and route of administration of 
GC. There is a need to optimise future studies to define 
the minimum effective initial dose and a safe reduction 
approach for managing GCA with GC.81 The treatment 
challenge of GC dependent or refractory/relapsing 
disease remains, particularly when reaching low-to-me-
dium doses of GC (10–15 mg/day). The three RCTs 
conducted to assess the role of MTX in newly diagnosed 
patients with GCA have been criticised for the applica-
tion of variable endpoints (time to first relapse, reduc-
tion of relapses or influence on cumulative GC dose), the 
use of different drug doses (maximum 15 mg/week) for 
a variable period of time, and for their heterogeneous 
adjunctive GC doses and tapering schemes. Only one of 
them had reached its primary endpoint.86 However, a 
meta-analysis of individual patient data assessed the role 
of MTX in preventing the first and subsequent relapse, 
confirming the efficacy and safety of MTX in both 
disease states and highlighting the relatively slow action 
of the drug within 2–3 months. MTX was confirmed to 
reduce the cumulative GC dose.89 Available evidence on 
the subsequent long-term use of MTX (although at a 
maximum dose of only 15 mg/week) in routine clinical 
care confirmed its efficacy and safety.90
The main novel therapeutic option for GCA in recent 
years has been TCZ.81 100 TCZ proved to be efficacious 
in newly diagnosed and relapsing patients in terms of 
reducing the risk of relapse and allowing a GC-free or 
low-GC dose remission. Continuous surveillance and 
future studies are needed to assess the optimal dose, 
duration of treatment and tapering speed of GC when 
prescribed concomitantly to TCZ. We do not have any 
reliable monitoring tests in patients receiving TCZ, which 
very effectively suppresses acute phase reactants; this 
might be clarified by longer term registry data.
The studies on the two main add-on therapies 
supported by high-quality evidence (MTX and TCZ) are 
characterised by differences in study outcomes, defini-
tions of relapse and remission, treatment duration, doses 
of concomitant GC and study effect sizes (lower for MTX) 
which do not allow direct comparisons between the two 
drugs. Only one of the three RCTs conducted on MTX 
reached its primary endpoint and the quality of the RCTs 
supporting the use of TCZ was higher. Nevertheless, no 
head-to-head comparative studies have been conducted 
to date. Moreover, there are no validated biomarkers of 
disease severity or extent to identify patients who should 
be treated more intensively from the onset of disease. All 
these questions will need to be addressed by the future 
studies.
In summary, the literature review confirms the need for 
prompt GC initiation in suspected GCA, the emerging 
role for imaging diagnostic tools, and the efficacy and 
safety of adjunctive therapy with MTX or TCZ. The review 
highlights some unresolved issues in terms of the optimal 
monitoring test(s), ability to detect complications and 
prophylactic treatment to prevent ischaemic, cardiovas-
cular or infectious events.
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